Detectable levels of poly-GP in the cerebrospinal fluid/CSF have been reported in the pre-symptomatic phase of C9orf72 mutation carriers [8] making it a candidate biomarker for C9orf72-ALS [8–12]. Here, C9orf72 is linked to amyotrophic lateral sclerosis.